CN1756559B - 稳定的含组织因子通路抑制剂或组织因子通路抑制剂变体的液体组合物 - Google Patents
稳定的含组织因子通路抑制剂或组织因子通路抑制剂变体的液体组合物 Download PDFInfo
- Publication number
- CN1756559B CN1756559B CN200480006044XA CN200480006044A CN1756559B CN 1756559 B CN1756559 B CN 1756559B CN 200480006044X A CN200480006044X A CN 200480006044XA CN 200480006044 A CN200480006044 A CN 200480006044A CN 1756559 B CN1756559 B CN 1756559B
- Authority
- CN
- China
- Prior art keywords
- tfpi
- compositions
- acid
- variant
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43851903P | 2003-01-08 | 2003-01-08 | |
US60/438,519 | 2003-01-08 | ||
US49457703P | 2003-08-13 | 2003-08-13 | |
US60/494,577 | 2003-08-13 | ||
US50926003P | 2003-10-08 | 2003-10-08 | |
US60/509,260 | 2003-10-08 | ||
US51209003P | 2003-10-20 | 2003-10-20 | |
US60/512,090 | 2003-10-20 | ||
PCT/US2004/000233 WO2004062689A1 (en) | 2003-01-08 | 2004-01-08 | Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1756559A CN1756559A (zh) | 2006-04-05 |
CN1756559B true CN1756559B (zh) | 2010-04-28 |
Family
ID=32719506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200480006044XA Expired - Fee Related CN1756559B (zh) | 2003-01-08 | 2004-01-08 | 稳定的含组织因子通路抑制剂或组织因子通路抑制剂变体的液体组合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20040224886A1 (es) |
EP (2) | EP1599222B1 (es) |
JP (1) | JP2006515882A (es) |
CN (1) | CN1756559B (es) |
AT (1) | ATE424215T1 (es) |
AU (1) | AU2004204720B2 (es) |
CA (1) | CA2512681A1 (es) |
CY (1) | CY1109096T1 (es) |
DE (1) | DE602004019761D1 (es) |
DK (1) | DK1599222T3 (es) |
EA (1) | EA008038B1 (es) |
ES (1) | ES2321297T3 (es) |
PT (1) | PT1599222E (es) |
SI (1) | SI1599222T1 (es) |
WO (1) | WO2004062689A1 (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US7375216B2 (en) * | 2002-06-04 | 2008-05-20 | Infacare Pharmaceutical Corporation | Preparation of metal mesoporphyrin compounds |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
ATE477020T1 (de) | 2002-06-07 | 2010-08-15 | Dyax Corp | Prevention und verringerung von ischemia |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
JP2005537006A (ja) | 2002-08-28 | 2005-12-08 | ダイアックス、コープ | 臓器及び組織の保存方法 |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
AU2006206272A1 (en) * | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
US7922823B2 (en) * | 2005-01-27 | 2011-04-12 | Advanced Technology Materials, Inc. | Compositions for processing of semiconductor substrates |
US20060222668A1 (en) * | 2005-04-01 | 2006-10-05 | Wellspring Pharmaceutical Corporation | Stannsoporfin compositions, drug products and methods of manufacture |
EP1898945B1 (en) | 2005-06-24 | 2012-12-19 | Drugrecure ApS | Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
WO2008005071A1 (en) * | 2006-03-03 | 2008-01-10 | Novartis Ag | Cell-based assay for measuring anti-proliferative activity of oxidized tfpi |
WO2007103425A2 (en) * | 2006-03-06 | 2007-09-13 | Novartis Ag | Kits and methods for preparing pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) |
CA2643693A1 (en) * | 2006-03-10 | 2007-09-20 | Dyax Corp. | Formulations for ecallantide |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
AU2007240507B2 (en) | 2006-04-21 | 2013-07-18 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
CN109503584A (zh) | 2006-05-04 | 2019-03-22 | 勃林格殷格翰国际有限公司 | 多晶型 |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
EA019864B1 (ru) | 2006-10-04 | 2014-06-30 | Инфакэар Фармасьютикал Корпорейшн | Крупномасштабное производство станнсопорфина высокой чистоты |
EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
JP4999613B2 (ja) * | 2007-08-31 | 2012-08-15 | シスメックス株式会社 | 血液凝固測定用試薬及び血液凝固時間測定方法 |
ES2393233T3 (es) * | 2007-11-01 | 2012-12-19 | Merck Serono S.A. | Formulaciones de LH líquidas |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
EP2385843A4 (en) | 2009-01-06 | 2013-02-27 | Dyax Corp | TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
JP2011001273A (ja) * | 2009-06-16 | 2011-01-06 | Eci Inc | eMIPを有効成分とする水溶性製剤 |
MX364651B (es) | 2009-11-27 | 2019-05-03 | Boehringer Ingelheim Int Gmbh Star | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente. |
DK2513134T3 (en) * | 2009-12-18 | 2017-12-18 | Novartis Ag | Washing solution and process for affinity chromatography |
CA3168591A1 (en) | 2010-01-06 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
EP2566469B1 (en) | 2010-05-05 | 2022-12-21 | Boehringer Ingelheim International GmbH | Combination therapy |
EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
JO3400B1 (ar) | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
EP3287123B1 (en) | 2011-03-04 | 2020-04-22 | Grünenthal GmbH | Aqueous pharmaceutical formulation of tapentadol for oral administration |
DK2691398T3 (en) | 2011-03-30 | 2017-01-16 | Infacare Pharmaceutical Corp | Methods for synthesizing metal mesoporphyrins |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
KR101759694B1 (ko) | 2011-10-28 | 2017-07-19 | 인테그리티 바이오, 아이엔씨. | 아미노산을 함유하는 단백질 제제 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2928903A4 (en) * | 2012-12-06 | 2016-08-31 | Tobira Therapeutics Inc | OLIGONUKLEOTIDREZEPTUR |
US20160058725A1 (en) * | 2013-03-15 | 2016-03-03 | Biochemics, Inc. | Topical Formulations and Methods for Drug Delivery |
WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
CN105153021A (zh) * | 2014-06-12 | 2015-12-16 | 浙江永宁药业股份有限公司 | 马来酸吡硫醇晶型及其制备方法 |
WO2016156147A1 (en) | 2015-03-27 | 2016-10-06 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
PE20190908A1 (es) | 2016-09-23 | 2019-06-26 | Gruenenthal Chemie | Formulacion estable para la administracion parenteral de tapentadol |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
EP0158487B1 (en) | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
US4650674A (en) | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
US5034225A (en) | 1985-12-17 | 1991-07-23 | Genentech Inc. | Stabilized human tissue plasminogen activator compositions |
JPH0645551B2 (ja) | 1986-01-07 | 1994-06-15 | 塩野義製薬株式会社 | インタ−ロイキン−2組成物 |
US4894226A (en) | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
EP0303746B2 (en) | 1987-08-21 | 1998-12-02 | Mallinckrodt Group Inc. | Stabilization of growth promoting hormones |
US4883661A (en) | 1987-10-09 | 1989-11-28 | Daly John M | Use of arginine as an lymphokine synergist |
US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
FR2684878B1 (fr) | 1991-12-12 | 1994-02-11 | Roussel Uclaf | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. |
IL107887A (en) | 1992-12-08 | 2003-07-06 | Ambi Inc | Stabilized lanthionine containing bacteriocin compositions |
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
EP0774001B1 (en) * | 1994-08-05 | 2002-10-16 | Chiron Corporation | Production of tissue factor pathway inhibitor |
JP2000510813A (ja) | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Il−12用処方 |
SE9501189D0 (sv) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
WO1996040784A2 (en) * | 1995-06-07 | 1996-12-19 | Chiron Corporation | Method of solubilizing, purifying, and refolding protein |
AU708394B2 (en) * | 1995-06-07 | 1999-08-05 | Novartis Vaccines And Diagnostics, Inc. | Regulation of cytokine synthesis and release |
US5888968A (en) * | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
US5977057A (en) * | 1996-05-08 | 1999-11-02 | The University Of Vermont And State Agricultural College | Thrombosis prophylaxis for factor VLEIDEN carriers |
US6262233B1 (en) * | 1997-01-31 | 2001-07-17 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
ATE367828T1 (de) | 1998-04-03 | 2007-08-15 | Novartis Vaccines & Diagnostic | Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel |
CZ20021186A3 (cs) * | 1999-10-04 | 2002-11-13 | Chiron Corporation | Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid |
WO2001036632A2 (en) * | 1999-11-17 | 2001-05-25 | Compugen Ltd. | Variants of alternative splicing |
DE60115422T2 (de) * | 2000-05-10 | 2006-08-17 | Novo Nordisk Health Care Ag | PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR |
AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
WO2002058734A2 (en) * | 2001-01-26 | 2002-08-01 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
US7074901B2 (en) * | 2001-05-25 | 2006-07-11 | Serono Genetics Institute S.A. | Isolated human vCOL16A1 polypeptide and fragments thereof |
-
2004
- 2004-01-08 EP EP04700828A patent/EP1599222B1/en not_active Expired - Lifetime
- 2004-01-08 PT PT04700828T patent/PT1599222E/pt unknown
- 2004-01-08 AU AU2004204720A patent/AU2004204720B2/en not_active Ceased
- 2004-01-08 SI SI200431119T patent/SI1599222T1/sl unknown
- 2004-01-08 EA EA200501097A patent/EA008038B1/ru not_active IP Right Cessation
- 2004-01-08 CA CA002512681A patent/CA2512681A1/en not_active Abandoned
- 2004-01-08 US US10/753,068 patent/US20040224886A1/en not_active Abandoned
- 2004-01-08 WO PCT/US2004/000233 patent/WO2004062689A1/en active Application Filing
- 2004-01-08 JP JP2006500805A patent/JP2006515882A/ja active Pending
- 2004-01-08 AT AT04700828T patent/ATE424215T1/de not_active IP Right Cessation
- 2004-01-08 EP EP08075968A patent/EP2174663A1/en not_active Withdrawn
- 2004-01-08 DK DK04700828T patent/DK1599222T3/da active
- 2004-01-08 CN CN200480006044XA patent/CN1756559B/zh not_active Expired - Fee Related
- 2004-01-08 DE DE602004019761T patent/DE602004019761D1/de not_active Expired - Lifetime
- 2004-01-08 ES ES04700828T patent/ES2321297T3/es not_active Expired - Lifetime
-
2005
- 2005-12-14 US US11/302,208 patent/US7659248B2/en not_active Expired - Fee Related
-
2009
- 2009-05-22 CY CY20091100554T patent/CY1109096T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1599222A1 (en) | 2005-11-30 |
EA008038B1 (ru) | 2007-02-27 |
CA2512681A1 (en) | 2004-07-29 |
DK1599222T3 (da) | 2009-04-27 |
CN1756559A (zh) | 2006-04-05 |
CY1109096T1 (el) | 2014-07-02 |
DE602004019761D1 (de) | 2009-04-16 |
AU2004204720B2 (en) | 2009-08-06 |
ATE424215T1 (de) | 2009-03-15 |
US20060079459A1 (en) | 2006-04-13 |
SI1599222T1 (sl) | 2009-08-31 |
ES2321297T3 (es) | 2009-06-04 |
US7659248B2 (en) | 2010-02-09 |
AU2004204720A1 (en) | 2004-07-29 |
EP2174663A1 (en) | 2010-04-14 |
WO2004062689A1 (en) | 2004-07-29 |
US20040224886A1 (en) | 2004-11-11 |
PT1599222E (pt) | 2009-06-12 |
EP1599222B1 (en) | 2009-03-04 |
EA200501097A1 (ru) | 2006-04-28 |
JP2006515882A (ja) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1756559B (zh) | 稳定的含组织因子通路抑制剂或组织因子通路抑制剂变体的液体组合物 | |
JP7003183B2 (ja) | 凍結乾燥した組換え型vwf製剤 | |
JP5784907B2 (ja) | 組換え型vwf製剤 | |
FI85334B (fi) | Foerfarande foer framstaellning av en vattenbaserad, vaevnadsplasminogenaktivator (t-pa) innehaollande, koncentrerad parenterad loesning. | |
FI85335C (fi) | Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition. | |
PT1491208E (pt) | Composições farmacêuticas contendo polipéptido líquidas estabilizadas | |
US20060159679A1 (en) | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants | |
JP2012506387A5 (es) | ||
JPH0925241A (ja) | Hgf凍結乾燥製剤 | |
CA2573307C (en) | Use of platelet aggregation inhibitors | |
PT1029548E (pt) | Método para manutenção da qualidade de uma solução parentérica de trombomodulina em armazenamento e distribuição. | |
AU662940B2 (en) | Stabilized pharmaceutical composition of non-glycosylated recombinant human IL2 in reduced form and its preparation process | |
JPH06247870A (ja) | インターロイキン−6を含有する医薬製剤 | |
KR20050023875A (ko) | 인간 성장 호르몬의 안정화된 액상 제제용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1090284 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: NOVARTIS VACCINES & DIAGNOSTIC Free format text: FORMER OWNER: CHIRON CORP. Effective date: 20080530 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Delaware Applicant after: Novartis Vaccines & Diagnostic Inc. Address before: American California Applicant before: Chiron Corporation |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100428 Termination date: 20110108 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1090284 Country of ref document: HK |